Last reviewed · How we verify

Ropivacaine Injection [Naropin]

Medical University Innsbruck · FDA-approved active Small molecule Quality 2/100

Ropivacaine Injection [Naropin] is a Small molecule drug developed by Medical University Innsbruck. It is currently FDA-approved. Also known as: Naropin, Erector spinae block.

At a glance

Generic nameRopivacaine Injection [Naropin]
Also known asNaropin, Erector spinae block
SponsorMedical University Innsbruck
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ropivacaine Injection [Naropin]

What is Ropivacaine Injection [Naropin]?

Ropivacaine Injection [Naropin] is a Small molecule drug developed by Medical University Innsbruck.

Who makes Ropivacaine Injection [Naropin]?

Ropivacaine Injection [Naropin] is developed and marketed by Medical University Innsbruck (see full Medical University Innsbruck pipeline at /company/medical-university-innsbruck).

Is Ropivacaine Injection [Naropin] also known as anything else?

Ropivacaine Injection [Naropin] is also known as Naropin, Erector spinae block.

What development phase is Ropivacaine Injection [Naropin] in?

Ropivacaine Injection [Naropin] is FDA-approved (marketed).

Related